AAFPRS Rejuvenation of the Aging Face January 18-22, 2012 San Diego, California Munich Facial Plastic Surgery 2012 February 14-17, 2012 Munich, Germany International Federation of Facial Plastic Surgery VII International Congress May 9-12, 2012 Rome, Italy JOIN US FOR A FREE SEMINAR! Upcoming Seminars Please stay tuned for our 2012 dates Click to hear more about seminar series

For more information: Linda Giangardella 330-758-2001 www.facialplastics.org

The FDA has approved Dysport to treat forehead wrinkles and frown lines, making it only the second drug to be approved by the agency as a wrinkle treatment.

Dysport (formerly known as Reloxin) is made from the same active ingredient as Botox (made by Allergan), Clostridium botulinim toxin type A. Botulinum toxins temporarily reduce the appearance of wrinkles by restricting the muscle actions that cause creasing and frown lines.

Like Botox, Dysport is administered via an injection at the site of forehead wrinkles. The FDA based its approval on clinical trials involving about 2,900 people at 80 study sites. Dysport has been used in Europe since the early 90’s
One clinical trial showed 93%-95% of participants noticed an improvement in the appearance of forehead wrinkles within seven days after treatment, and multiple treatments produced effects that lasted for more than 13 months.

The most common side effects of Dysport are nose and throat irritation, headache, pain and skin reaction at the injection site, upper respiratory tract infection, eyelid swelling or drooping, sinus inflammation, and nausea.